Wearable inertial measurement units (IMUs) can be utilized as an alternative to optical motion capture as a method of measuring joint angles. These sensors require functional calibration prior to data collection, known as sensor-to-segment calibration. This study aims to evaluate previously described sensor-to-segment calibration methods to measure joint angle range of motion (ROM) during highly dynamic sports-related movements. Seven calibration methods were selected to compare lower extremity ROM measured using IMUs to an optical motion capture system. The accuracy of ROM measurements for each calibration method varied across joints and sport-specific tasks, with absolute mean differences between IMU measurement and motion capture measurement ranging from <0.1° to 24.1°. Fewer significant differences were observed at the pelvis than at the hip, knee, or ankle across all tasks. For each task, one or more calibration movements demonstrated non-significant differences in ROM for at least nine out of the twelve ROM variables. These results suggest that IMUs may be a viable alternative to optical motion capture for sport-specific lower-extremity ROM measurement, although the sensor-to-segment calibration methods used should be selected based on the specific tasks and variables of interest for a given application.
We leveraged transcriptomic data from 4,343 participants from four independent datasets to robustly identify and annotate circulating PD-associated transcripts. We identified 296 differentially expressed transcripts, 28 of which were transcribed from known PD-associated loci. Further, we found a significant overlap between our findings and transcripts dysregulated in brain, as well as proteins differentially accumulated in CSF. Expression of the identified transcripts was affected by genetic background including ancestry and PD-related mutations, and nearly half of the identified transcripts were dysregulated before symptom onset. The differentially expressed transcripts were utilized to develop three predictive models that distinguished between PD and healthy controls with a ROC AUC of 0.727-0.733. The predictive models were capable of detecting PD transcriptomic signatures even before symptom onset. One transcript, DLD, showed particular promise as an early stage, minimally invasive PD biomarker that was differentially expressed in whole blood, brain and CSF. This transcript significantly related to PD in the eQTL analyses and in two of the three predictive models.